MIST Milestone Pharmaceuticals Inc.

NASDAQ
$1.10

Milestone Pharmaceuticals Inc. (MIST) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.9% since its last earnings release on August 12, 2026.

Milestone Pharmaceuticals Missed Consensus Estimates
Wednesday, August 12, 2026 · 7:08 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 7:10 AM ET
Earnings Whisper
-
vs ($0.20)
Rev est $1.47M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.11

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada.

Sector

Healthcare

Industry

Biotechnology